Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: biao luo who wrote (636)	12/22/1997 2:58:00 PM
From: Czechsinthemail	Read Replies (1) of 887

biao luo, Thanks for another excellent post. I agree that the leukemia and lymphomas comparisons should be more favorable to DepoCyt both on efficacy and side effects profiles. Perhaps even more significant may be the additional solid tumor studies, which may help make the statistical case when added to the previously submitted data. AS it was, even using the "intend to treat" analysis, DepoCyt's efficacy seemed to be somewhat better than the methotrexate control group. Hopefully, more numbers would further substantiate that benefit. I, too, would like to know the story on the "intend to treat" and "evaluable" differences. Erickson did seem upset and suggested that the ODAC committee had reneged on previously negotiated understandings with the FDA. Since I don't know what those agreements may have been, it is hard to evaluate his response. Maybe he felt justifiably angry and betrayed and was trying hard to contain it. I can certainly relate to that feeling. Baird

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next